MK-0646

DRUG4 trials

Sponsors

Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Breast CancerMetastatic Colorectal CancerMetastatic Neuroendocrine TumorsNeuroendocrine TumorsPancreatic AdenocarcinomaPancreatic Cancer

Phase 1

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

CompletedNCT00769483

M.D. Anderson Cancer CenterPancreatic Adenocarcinoma, Pancreatic Cancer

Start: 2008-11-13End: 2020-09-01Updated: 2020-09-03

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

TerminatedNCT00903006

M.D. Anderson Cancer CenterBreast Cancer

Start: 2009-11-30End: 2013-05-31Updated: 2015-02-02

Phase 2

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

CompletedNCT00610129

Memorial Sloan Kettering Cancer CenterMetastatic Neuroendocrine Tumors, Neuroendocrine Tumors

Start: 2008-01-31End: 2010-01-31Updated: 2015-11-20

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

WithdrawnNCT01175291

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Colorectal Cancer

Start: 2010-09-30End: 2012-07-31Updated: 2011-12-05

Related Papers

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

2018-05-3040 citations